Search Results

Diagnosis: Relapsed/refractory AML (APL excluded) unsuitable for standard therapy. If relapsed, no more than 2 relapses are allowed. If refractory, must be primary refractory to at least 1 induction regimen. �Must have ability and willingness to give informed consent. �Patients must, in the opinion of the investigator, be capable of complying with the protocol. �Life expectancy greater than 12 weeks �Age greater than 18 years of age �Must be in fair to good physical condition with good organ function. �Men and women of childbearing potential (WOCBP) must be using an acceptable method of contraception to avoid pregnancy throughout the study for at least 70 days (for women) and 180 days (for men) following the last dose of study drug �Women must not be pregnant or nursing �Must be at least 2 weeks since prior cytotoxic, biologic, monoclonal antibody, or investigational therapy, except for hydroxyurea which can continue up to the day before start of study. �May not have had prior anti-CXCR4 therapy. �May not have had use of other investigational drugs within 2 weeks before start of study. �May not have had major surgery within 4 weeks before start of study. �May not have another cancer requiring cytotoxic therapy. �May not be HIV positive or may not have active autoimmune disease requiring immunosuppressive therapy. �May not have active infection with Hepatitis B, Hepatitis C, or tuberculosis. �May not have active GVHD or life threatening active bleeding. �May not have active infection requiring IV systemic therapy within 7 days before receiving the first dose of study drug. �May not have central nervous system leukemia. �May not have made donation of blood or plasma to a blood bank or in a clinical study (except a screening visit) within 4 weeks before start of study. �For patients who have had prior bone marrow transplant for AML, bone marrow transplant must have been greater than 3 months ago. �May not have current drug or alcohol abuse. �Must have ability to be venipunctured and/or tolerate venous access. �May not have history of hypersensitivity or allergy to monoclonal antibodies or related compounds. May not have a history of significant drug allergy (i.e. anaphylaxis or liver failure).